Compare Johnson & Johnson (JNJ) vs SS&C Technologies Holdings Inc. Common Stock (SSNC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs SS&C Technologies Holdings Inc. Common Stock — how do they compare? Johnson & Johnson trades at $257.97 (market cap $611.90B), while SS&C Technologies Holdings Inc. Common Stock trades at $82.08 (market cap $19.25B). The key difference: Johnson & Johnson is far larger — about 31.8× SS&C Technologies Holdings Inc. Common Stock's market cap, and Johnson & Johnson pays the higher dividend (2.11%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and SS&C Technologies Holdings Inc. Common Stock for 0 Days on average.
| JNJ | SSNC | |
|---|---|---|
Market Cap | $611.90B | $19.25B |
Volume | 9,651,904 | 1,341,767 |
Sector | Health | Technology |
52-Week High | $278.43 | $89.62 |
52-Week Low | $186.00 | $62.05 |
Typical Hold Time | 129 Days | 0 Days |
Enterprise Value | $640.18B | $26.59B |
Dividend Yield | 2.11% | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $248.61, down 5.73% in the last session, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q3 2026 earnings, beating estimates with $2.59 EPS versus $2.52 expected, continuing a trend of three consecutive quarterly beats. JNJ maintains robust profitability with 67.91% gross margins and 21.48% net income margins, supported by $94.19B in 2025 revenue and $26.80B net income.
Analyst consensus remains positive with 52.5% buy ratings and a $282.53 price target, representing 13.6% upside potential. Key risks include patent cliffs affecting pharmaceutical revenue and increasing debt-to-asset ratio reaching 24.06% in 2025. The company's diversified healthcare portfolio and strong dividend history provide stability, while new drug launches like Icotyde offer growth catalysts.
SSNC trades at $81.52, up 0.65% on the day, with a neutral technical signal. The company has consistently beaten earnings estimates in recent quarters (Q4 2025, Q1 2026, Q2 2026) and shows solid fundamentals, including a 13.16% net income margin and 12.73% ROE. Recent news highlights new client wins and AI-driven product enhancements, reinforcing its market position.
The outlook is positive, supported by strong analyst consensus (70.83% Buy rating) and a $91.50 price target, implying ~12% upside. Key risks include execution of growth initiatives and competitive pressures in the financial technology sector. The stock presents a compelling opportunity for investors seeking a fundamentally sound company with recurring revenue streams.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About SS&C Technologies Holdings Inc. Common Stock
SS&C Technologies Holdings, Inc. provides software and outsourced services for financial services and healthcare organizations, covering fund accounting, portfolio management, trading support, and regulatory reporting, and operates as a hedge fund and private equity administrator and mutual fund transfer agent.
Read more on SSNC →
